Survodutide advances metabolic disease treatment, while biosimilar capacity expands, FDA delays hemophilia review, and lupus data support next steps.
|Articles|March 22, 2007
FDA Has a New CIO
Author(s)BioPharm International Editors
Timothy Stitely will become FDA's chief information officer (CIO) effective March 5, 2007.
Advertisement
Timothy Stitely will become FDA’s chief information officer (CIO) effective March 5, 2007. In his role as the FDA CIO, Tim will strengthen the agency’s information technology infrastructure. Tim brings a wealth of experience developing and managing innovative and cost-effective multi-organizational programs in addition to extensive governmental re-engineering and streamlining experience. Before joining FDA, Tim served as the director of information services design and development group with the Centers for Medicare and Medicaid Services (CMS).
Advertisement
Related to this article
Litifilimab extended skin responses through 52 weeks in phase 2 AMETHYST data in cutaneous lupus erythematosus, with phase 3 results expected in 2027.
Manufacturing remediation, not efficacy or safety data, is delaying US approval of Novo's h+emophilia A therapy denecimig.
Doubled drug substance capacity at Alvotech's Reykjavik, Iceland, site aims to secure steady US supply of the Humira biosimilar Simlandi.
The glucagon/GLP-1 dual agonist hit both weight loss endpoints in phase 3, though gastrointestinal discontinuations and competitor data temper the readout.
CaseBioscience joins an ARPA-H effort to develop room-temperature cell therapy preservation, Novartis licenses an mRNA-encoded T-cell engager from Abogen, and AstraZeneca, Daiichi Sankyo, and Summit plan to combine Datroway with ivonescimab.
LumaLex Law's Dustin Robinson explains why retatrutide compounding remains illegal regardless of the Seventh Circuit's pending classification ruling.
Artiva Biotherapeutics will present data on AlloNK, an allogeneic, non-genetically modified NK cell therapy given with rituximab, in refractory rheumatoid arthritis, Sjögren disease and systemic sclerosis at ACR Convergence 2026, ahead of a planned phase 3 trial in rheumatoid arthritis.
Advertisement
Advertisement